Bristol-Myers Squibb has signed an agreement worth $475 million to develop a new form of cancer immunotherapy drug with US biotech Dragonfly Therapeutics. BMS is best known as an early pioneer of ...

The same year, Novartis acquired the North American over-the-counter brand portfolio of Bristol-Myers Squibb. In 2006, Novartis announced the creation of a biomedical R&D centre in Shangai, China.

Cigna claims Bristol Myers’ Celgene unit filed sham lawsuits it knew it was unlikely to win in an effort to protect its ...

Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis ...

Investors have been keeping a sharp eye on Bristol Myers as its stock has lagged behind peers recently. Bristol Myers’ stock ...

Stay up to date on how Bristol-Myers Squibb Co (BMY:XNYS) stock has performed compared to similar stocks in the same industry on a daily, quarterly, and monthly basis.

Check out the latest Bristol Myers Squibb Co. (BMY) stock quote and chart. View real-time stock prices & the company’s financial overview to help with your trading & investment.

Access to and affordability of immune checkpoint inhibitors, which can be lifesaving if patients receive them on time and ...

Bristol-Myers Squibb is testing MORAb-202 in a Phase 2 trial to challenge traditional chemotherapy for platinum-resistant ...